Biohaven Licenses Kv7 Epilepsy Platform to SK Biopharmaceuticals for up to $795M

Biohaven (NYSE: BHVN) is handing worldwide rights to its Kv7 ion channel platform and lead epilepsy candidate opakalim (BHV-7000) to South Korea’s SK Biopharmaceuticals in a deal worth up to $795 million. The transaction brings Biohaven roughly $400 million in near-term cash, leaves SK to fund and run development toward a hoped-for 2029 U.S. launch, and sent Biohaven shares up 18% to $16.95 on 15.8 million shares traded, well above the stock’s typical volume.

The headline number breaks down fast, as this guide to licensing-deal economics explains. Biohaven receives $350 million upfront at closing, another $50 million in 2027, and up to $150 million in development and regulatory milestones, plus tiered royalties of mid-teens to low-20s on U.S. net sales of opakalim. SK also assumes $245 million of Biohaven’s existing obligations: up to $185 million payable to Knopp Biosciences upon U.S. and EU approval, and up to $60 million tied to future Kv7 pipeline programs.

Opakalim is a selective Kv7.2/7.3 potassium channel activator, an oral once-daily pill designed to calm overactive neurons without the sedation and dizziness that weigh on older antiseizure drugs. Kv7 channels act as the brain’s natural brake on firing; opening them quiets overactive neurons. The pitch is that selective Kv7.2/7.3 activation, with no GABA activity, delivers seizure control with fewer cognitive side effects. Epilepsy affects roughly 3 million U.S. adults, and up to half of people with focal seizures still lack adequate control on existing drugs, which is why a tolerability-first option matters.

Biohaven keeps running the ongoing Phase 2/3 trials, while SK covers development costs from here. Topline results from the RISE3 trial are expected in the second half of 2026, and SK’s Korean regulatory filing points to a 2029 U.S. launch.

The bet is a crowded one. Xenon Pharmaceuticals’ azetukalner, another Kv7 opener, reported positive Phase 3 X-TOLE2 data in March showing a 53.2% reduction in monthly focal seizures versus 10.4% for placebo, and Xenon is targeting an FDA filing this year. Opakalim would arrive into a market where a Kv7 competitor may already be entrenched, and it is a year or more behind.

The risk for Biohaven shareholders is what the company gave up: it keeps royalties and milestones, but SK owns the commercialization upside it once intended to build itself. Watch the RISE3 readout in the second half of 2026. If opakalim’s tolerability holds up against azetukalner’s already-strong data, SK’s Xcopri sales force gets a genuine second act.

What It Means for the Trade

The 18% pop on the announcement tells you what the market really thought of Biohaven running this program alone: the deal was read as risk transfer at a fair-to-generous price, not a fire sale. Run the cash math: roughly $400 million near-term ($350 million upfront at closing, $50 million in 2027) plus SK assuming $245 million of Biohaven’s existing obligations — the Knopp approval milestones and Kv7 pipeline commitments — for a company that had just cut R&D spending 60% after troriluzole’s CRL. That is balance-sheet repair plus concentration reduction in one transaction. The mid-teens to low-20s royalty band on U.S. sales preserves meaningful upside if opakalim wins, but the trade-off is structural: SK now owns the launch economics, the sales-force buildout, and the commercial ceiling. Biohaven shareholders traded the distribution rights for survival currency.

The read on deal quality is honest in both directions. $795 million headline on a Phase 2/3 asset with positive-class-adjacent competitor data (Xenon’s azetukalner) is a solid but not spectacular package — the milestone-heavy structure means Biohaven only realizes the full number if opakalim actually succeeds through approval and launch. What the deal does do is pre-fund the rest of the pipeline through the period when the Kv7 binary would have been most dangerous to own. Biohaven keeps running the RISE trials while SK pays — that is a partner covering your binary risk in exchange for your upside, which is the standard trade for a company that can’t afford the binary.

Mechanism and Competitive Context

The program’s commercial identity is tolerability-first. Kv7.2/7.3 activation quiets neurons through the M-current — the brain’s endogenous excitability damper — without GABA engagement, which is why the class promises seizure control without the cognitive fog, sedation, and dizziness that drive discontinuation in up to half of focal-epilepsy patients inadequately controlled on current drugs. Roughly 3 million U.S. adults have epilepsy, and treatment-resistant focal seizures are the population every new mechanism is fighting over. The catch is the class race: azetukalner’s X-TOLE2 (53.2% monthly focal seizure reduction versus 10.4% placebo) has set the bar, and Xenon is targeting a filing this year. Opakalim arrives at minimum a year behind, into a market where the first launched Kv7 defines prescriber expectations. SK’s Xcopri franchise gives it an epilepsy commercial channel Biohaven never built — that is the strategic logic from SK’s side, a second epilepsy product to detail through an existing salesforce.

The 2029 U.S. launch target implied by SK’s Korean filing is the number to anchor timelines on — it assumes approval and a standard review, which makes the RISE3 readout the only 2026 event that matters for the asset’s value.

Risks and What Could Go Wrong

1. RISE3 misses: with the platform out-licensed, a Phase 3 failure converts Biohaven’s retained value into just the $350 million already banked, and the stock gives back the deal-pop.
2. Azetukalner launches first and captures the refractory-focal niche, leaving opakalim a late entrant fighting for switch patients on tolerability claims alone.
3. Milestone dependence: Biohaven’s economics from here are contingent on events (approval, launch) it no longer controls — a partner’s commercial decisions become unanalyzable external risk.
4. The remaining Biohaven pipeline has to carry the equity story without Kv7’s launch economics — portfolio concentration post-deal is the new risk the 18% rally is not discounting.

Position read: the deal de-risked the balance sheet at the cost of the upside — a rational trade for a company in Biohaven’s position. The tradeable catalyst is still RISE3 in H2 2026, now expressed through retained royalties rather than full economics. Size accordingly: the asset’s equity beta to the readout is materially lower than it was a week before the deal.

Source: Biohaven and SK Biopharmaceuticals press release